Estrogen improves TIMP-MMP balance and collagen distribution in volume-overloaded hearts of ovariectomized females

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 299, Issue 2, 2010, Pages

  Voloshenyuk, Tetyana G ^a   Gardner, Jason D ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Collagen; Extracellular matrix remodeling; Gender; Hormone; Hypertrophy; MT1 MMP; Ovariectomy; Ventricle

Indexed keywords

COLLAGEN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; SCLEROPROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DOWN REGULATION; EXTRACELLULAR MATRIX; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION; WESTERN BLOTTING;

ANIMALS; COLLAGEN; DISEASE MODELS, ANIMAL; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN REPLACEMENT THERAPY; FEMALE; FIBROSIS; HEART FAILURE; HYPERTROPHY, LEFT VENTRICULAR; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MYOCARDIUM; OVARIECTOMY; RATS; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TISSUE INHIBITOR OF METALLOPROTEINASES; VENTRICULAR REMODELING;

EID: 77955479086     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00162.2010     Document Type: Article

References (64)

1. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR. Matrix metalloproteinases/ tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113: 2089-2096, 2006.
2. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van HL, Wactawski-Wende J, Wallace R, and Wassertheil-Smoller S. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291: 1701-1712, 2004.
3. Bigg HF, Shi YE, Liu YE, Steffensen B, Overall CM. Specific, high-affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP-4) to the COOH-terminal hemopexin-like domain of human gelatinase A. TIMP-4 binds progelatinase A and the COOH-terminal domain in a similar manner to TIMP-2. J Biol Chem 272: 15496-15500, 1997.
4. Bishop JE, Greenbaum R, Gibson DG, Yacoub M, Laurent GJ. Enhanced deposition of predominantly type I collagen in myocardial disease. J Mol Cell Cardiol 22: 1157-1165, 1990.
5. Brower GL, Chancey AL, Thanigaraj S, Matsubara BB, Janicki JS. Cause and effect relationship between myocardial mast cell number and matrix metalloproteinase activity. Am J Physiol Heart Circ Physiol 283: H518-H525, 2002.
6. Brower GL, Gardner JD, Janicki JS. Gender-mediated cardiac protection from adverse ventricular remodeling is abolished by ovariectomy. Mol Cell Biochem 251: 89-95, 2003.
7. Clark AL, Slayden OD, Hettrich K, Brenner RM. Estrogen increases collagen I and III mRNA expression in the pelvic support tissues of the rhesus macaque. Am J Obstet Gynecol 192: 1523-1529, 2005.
8. Dai Q, Lin J, Craig T, Chou YM, Hinojosa-Laborde C, Lindsey ML. Estrogen effects on MMP-13 and MMP-14 regulation of left ventricular mass in Dahl salt-induced hypertension. Gend Med 5: 74-85, 2008.
9. Etique N, Grillier-Vuissoz I, Flament S. Ethanol stimulates the secretion of matrix metalloproteinases 2 and 9 in MCF-7 human breast cancer cells. Oncol Rep 15: 603-608, 2006.
10. Francisco YA, Dantas AP, Carvalho MH, Laurindo FR. Estrogen enhances vasoconstrictive remodeling after injury in male rabbits. Braz J Med Biol Res 38: 1325-1329, 2005.
11. Gabel SA, Walker VR, London RE, Steenbergen C, Korach KS, Murphy E. Estrogen receptor beta mediates gender differences in ischemia/ reperfusion injury. J Mol Cell Cardiol 38: 289-297, 2005.
12. Gardner JD, Brower GL, Janicki JS. Gender differences in cardiac remodeling secondary to chronic volume overload. J Card Fail 8: 101-107, 2002.
13. Gardner JD, Brower GL, Voloshenyuk TG, Janicki JS. Cardioprotection in female rats subjected to chronic volume overload: synergistic interaction of estrogen and phytoestrogens. Am J Physiol Heart Circ Physiol 294: H198-H204, 2008.
14. Gardner JD, Murray DB, Voloshenyuk TG, Brower GL, Bradley JM, Janicki JS. Estrogen attenuates chronic volume overload induced structural and functional remodeling in male rat hearts. Am J Physiol Heart Circ Physiol 298: H497-H504, 2010.
15. Geraldes P, Geoffroy P, Cloutier I, Sirois MG, Tanguay JF. Local delivery of 17-β-estradiol modulates collagen content in coronary porcine arteries after PTCA and stent implantation. J Vasc Res 45: 503-511, 2008.
16. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 288: 49-57, 2002. (Pubitemid 34705518)
17. Graham HK, Horn M, Trafford AW. Extracellular matrix profiles in the progression to heart failure. Eur Young Physiol Symp Keynote Lecture-Bratislava Acta Physiol (Oxf) 194: 3-21, 2008.
18. Grandas OH, Mountain DJ, Kirkpatrick SS, Rudrapatna VS, Cassada DC, Stevens SL, Freeman MB, Goldman MH. Effect of hormones on matrix metalloproteinases gene regulation in human aortic smooth muscle cells. J Surg Res 148: 94-99, 2008.
19. Hernandez-Barrantes S, Shimura Y, Soloway PD, Sang QA, Fridman R. Differential roles of TIMP-4 and TIMP-2 in pro-MMP-2 activation by MT1-MMP. Biochem Biophys Res Commun 281: 126-130, 2001.
20. Herrington DM. The HERS trial results: paradigms lost? Heart and Estrogen/progestin Replacement Study. Ann Intern Med 131: 463-466, 1999.
21. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S, Eaton CB, Kostis JB, Caralis P, Prentice R. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 166: 357-365, 2006. (Pubitemid 43244325)
22. Hutchinson KR, Stewart JA Jr. Lucchesi PA. Extracellular matrix remodeling during the progression of volume overload-induced heart failure. J Mol Cell Cardiol 48: 564-569, 2009.
23. Iimoto DS, Covell JW, Harper E. Increase in cross-linking of type I and type III collagens associated with volume-overload hypertrophy. Circ Res 63: 399-408, 1988.
24. Irie T, Takahata M, Majima T, Abe Y, Komatsu M, Iwasaki N, Minami A. Effect of selective estrogen receptor modulator/raloxifene analogue on proliferation and collagen metabolism of tendon fibroblast. Connect Tissue Res 51: 179-187, 2010.
25. Jazbutyte V, Hu K, Kruchten P, Bey E, Maier SK, Fritzemeier KH, Prelle K, Hegele-Hartung C, Hartmann RW, Neyses L, Ertl G, Pelzer T. Aging reduces the efficacy of estrogen substitution to attenuate cardiac hypertrophy in female spontaneously hypertensive rats. Hypertension 48: 579-586, 2006.
26. Jeanes HL, Tabor C, Black D, Ederveen A, Gray GA. Oestrogen-mediated cardioprotection following ischaemia and reperfusion is mimicked by an oestrogen receptor (ER) alpha agonist and unaffected by an ER beta antagonist. J Endocrinol 197: 493-501, 2008.
27. Lam KK, Cheng PY, Hsiao G, Chen SY, Shen HH, Yen MH, Lee YM. Estrogen deficiency-induced alterations of vascular MMP-2, MT1-MMP, and TIMP-2 in ovariectomized rats. Am J Hypertens 22: 27-34, 2009.
28. Li H, Simon H, Bocan TM, Peterson JT. MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition. Cardiovasc Res 46: 298-306, 2000.
29. Li YY, Feldman AM, Sun Y, McTiernan CF. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 98: 1728-1734, 1998.
30. Lin J, Davis HB, Dai Q, Chou YM, Craig T, Hinojosa-Laborde C, Lindsey ML. Effects of early and late chronic pressure overload on extracellular matrix remodeling. Hypertens Res 31: 1225-1231, 2008.
31. Lindsey M, Lee RT. MMP inhibition as a potential therapeutic strategy for CHF. Drug News Perspect 13: 350-354, 2000.
32. Luchner A, Brockel U, Muscholl M, Hense HW, Doring A, Riegger GA, Schunkert H. Gender-specific differences of cardiac remodeling in subjects with left ventricular dysfunction: a population-based study. Cardiovasc Res 53: 720-727, 2002.
33. Machens K, Schmidt-Gollwitzer K. Issues to debate on the Women's Health Initiative (WHI) study hormone replacement therapy: an epidemiological dilemma? Hum Reprod 18: 1992-1999, 2003.
34. Mahmoodzadeh S, Dworatzek E, Fritschka S, Pham TH, Regitz-Zagrosek V. 17β-Estradiol inhibits matrix metalloproteinase-2 transcription via MAP kinase in fibroblasts Cardiovasc Res 85: 719-728, 2010.
35. Marijianowski MMH, Teeling P, Mann J, Becker AE. Dilated cardiomyopathy is associated with an increase in the type I/type III collagen ratio: A quantitative assessment. J Am Coll Cardiol 25: 1263-1272, 1995.
36. Mensah-Brown EP, Rizk DE, Patel M, Chandranath SI, Adem A. Effects of ovariectomy and hormone replacement on submucosal collagen and blood vessels of the anal canal of rats. Colorectal Dis 6: 481-487, 2004.
37. Meyer FJ, Burnand KG, Abisi S, TeKoppele JM, van EB, Smith A. Effect of collagen turnover and matrix metalloproteinase activity on healing of venous leg ulcers. Br J Surg 95: 319-325, 2008.
38. Miller AP, Xing D, Feng W, Fintel M, Chen YF, Oparil S. Aged rats lose vasoprotective and anti-inflammatory actions of estrogen in injured arteries. Menopause 14: 251-260, 2007.
39. Motulsky HJ. Intuitive Biostatistics. New York: Oxford University Press, 1995.
40. Mukherjee D, Sen S. Collagen phenotypes during development and regression of myocardial hypertrophy in spontaneously hypertensive rats. Circ Res 67: 1474-1480, 1990.
41. Nordmeyer J, Eder S, Mahmoodzadeh S, Martus P, Fielitz J, Bass J, Bethke N, Zurbrugg HR, Pregla R, Hetzer R, Regitz-Zagrosek V. Upregulation of myocardial estrogen receptors in human aortic stenosis. Circulation 110: 3270-3275, 2004.
42. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 272: 2446-2451, 1997.
43. Pauschinger M, Doerner A, Remppis A, Tannhäuser R, Kühl U, Schultheiss HP. Differential myocardial abundance of collagen type I and type III mRNA in dilated cardiomyopathy: effects of myocardial inflammation. Cardiovasc Res 37: 123-129, 1998.
44. Pauschinger M, Knopf D, Petschauer S, Doerner A, Poller W, Schwimmbeck PL, Kuhl U, Schultheiss HP. Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation 99: 2750-2756, 1999.
45. Pedram A, Razandi M, Lubahn D, Liu J, Vannan M, Levin ER. Estrogen inhibits cardiac hypertrophy: role of estrogen receptor-beta to inhibit calcineurin. Endocrinology 149: 3361-3369, 2008.
46. Arias-Loza PA, Hu K, Dienesch C, Mehlich AM, Konig S, Jazbutyte V, Neyses L, Hegele-Hartung C, Heinrich FK, Pelzer T. Both estrogen receptor subtypes, alpha and beta, attenuate cardiovascular remodeling in aldosterone salt-treated rats. Hypertension 50: 432-438, 2007.
47. Rizk DE, Hassan HA, Al-Marzouqi AH, Ramadan GA, Al-Kedrah SS, Daoud SA, Fahim MA. Combined estrogen and ghrelin administration restores number of blood vessels and collagen type I/III ratio in the urethral and anal canal submucosa of old ovariectomized rats. Int Urogynecol J Pelvic Floor Dysfunct 19: 547-552, 2008.
48. Russo LA, Peano BJ, Trivedi SP, Cavalcanto TD, Olenchock BA, Caruso JA, Smolock AR, Vishnevsky O, Gardner RM. Regulated expression of matrix metalloproteinases, inflammatory mediators, and endometrial matrix remodeling by 17beta-estradiol in the immature rat uterus. Reprod Biol Endocrinol 7: 124, 2009.
49. Skavdahl M, Steenbergen C, Clark J, Myers P, Demianenko T, Mao L, Rockman HA, Korach KS, Murphy E. Estrogen receptor-beta mediates male-female differences in the development of pressure overload hypertrophy. Am J Physiol Heart Circ Physiol 288: H469-H476, 2005.
50. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 90: 520-530, 2002.
51. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 87: 1285-1342, 2007.
52. Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure. Relation to ventricular and myocyte function. Circ Res 82: 482-495, 1998.
53. Stewart JA Jr, Cashatt DO, Borck AC, Brown JE, Carver WE. 17β-estradiol modulation of angiotensin II-stimulated response in cardiac fibroblasts. J Mol Cell Cardiol 41: 97-107, 2006.
54. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 97: 1708-1715, 1998.
55. Toth M, Hernandez-Barrantes S, Osenkowski P, Bernardo MM, Gervasi DC, Shimura Y, Meroueh O, Kotra LP, Galvez BG, Arroyo AG, Mobashery S, Fridman R. Complex pattern of membrane type 1 matrix metalloproteinase shedding. Regulation by autocatalytic cells surface inactivation of active enzyme. J Biol Chem 277: 26340-26350, 2002.
56. Tozzi R, Palladini G, Fallarini S, Nano R, Gatti C, Presotto C, Schiavone A, Micheletti R, Ferrari P, Fogari R, Perlini S. Matrix metalloprotease activity is enhanced in the compensated but not in the decompensated phase of pressure overload hypertrophy. Am J Hypertens 20: 663-669, 2007.
57. Tyagi SC, Campbell SE, Reddy HK, Tjahja E, Voelker DJ. Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts. Mol Cell Biochem 155: 13-21, 1996.
58. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92: 827-839, 2003.
59. Wei S, Chow LT, Shum IO, Qin L, Sanderson JE. Left and right ventricular collagen type I/III ratios and remodeling post-myocardial infarction. J Card Fail 5: 117-126, 1999.
60. Woodiwiss AJ, Tsotetsi OJ, Sprott S, Lancaster EJ, Mela T, Chung ES, Meyer TE, Norton GR. Reduction in myocardial collagen crosslinking parallels left ventricular dilatation in rat models of systolic chamber dysfunction. Circulation 103: 155-160, 2001.
61. Xu Y, Arenas IA, Armstrong SJ, Davidge ST. Estrogen modulation of left ventricular remodeling in the aged heart. Cardiovasc Res 57: 388-394, 2003.
62. Yang CM, Kandaswamy V, Young D, Sen SH. Changes in collagen phenotypes during progression and regression of cardiac hypertrophy. Cardiovasc Res 36: 236-245, 1997.
63. Yu HP, Shimizu T, Choudhry MA, Hsieh YC, Suzuki T, Bland KI, Chaudry IH. Mechanism of cardioprotection following trauma-hemorrhagic shock by a selective estrogen receptor-beta agonist: up-regulation of cardiac heat shock factor-1 and heat shock proteins. J Mol Cell Cardiol 40: 185-194, 2006.
64. Zhang Y, Stewart KG, Davidge ST. Estrogen replacement reduces age-associated remodeling in rat mesenteric arteries. Hypertension 36: 970-974, 2000.